

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

Claims 1-19 (Cancelled).

Claim 20. (New) A method of preventing a Group B streptococcal disease or disorder in a subject comprising administering to a subject in need thereof an effective amount of a composition comprising an isolated peptide, which comprises an amino acid sequence at least 95% similar to SEQ ID NO: 13, wherein said peptide induces antibodies that specifically bind to a polypeptide consisting of SEQ ID NO: 13.

Claim 21. (New) The method of claim 20, wherein said amino acid sequence is found in *Streptococcus agalactiae*.

Claim 22. (New) The method of claim 20, wherein said peptide comprises SEQ ID NO: 13.

Claim 23. (New) The method of claim 22, wherein said peptide is encoded by a polynucleotide comprising SEQ ID NO: 12.

Claim 24. (New) The method of claim 20, wherein said peptide further comprising a heterologous peptide.

Claim 25. (New) The method of claim 24, wherein said heterologous peptide is a His tag.

Claim 26. (New) The method of claim 20, wherein said composition further comprises a carrier.

Claim 27. (New) The method of claim 26, wherein said composition further comprises an adjuvant.

Claim 28. (New) The method of claim 27, wherein said adjuvant is alum.

Claim 29. (New) The method of claim 20, wherein said subject is an animal.

Claim 30. (New) The method of claim 29, wherein said animal is a human or a cow.

Claim 31. (New) The method of claim 20, wherein said composition elicits an immune response.

Claim 32. (New) The method of claim 20, wherein said disease or disorder is selected from the group consisting of: a Group B *Streptococcus* infection, septicemia, pneumonia, osteomyelitis, septic arthritis, abscesses, endophthalmitis, urinary track infection, and chronic mastitis.

Claim 33. (New) The method of claim 32, wherein said disease or disorder is a Group B *Streptococcus* infection.

Claim 34. (New) The method of claim 32, wherein said disease or disorder is a urinary track infection.

Claim 35. (New) A method of treating a disease or disorder in a subject comprising administering to a subject in need thereof an effective amount of a composition comprising an isolated peptide, which comprises an amino acid sequence at least 95% similar to SEQ ID NO: 13, wherein said peptide induces antibodies that specifically bind to a polypeptide consisting of SEQ ID NO: 13.

Claim 36. (New) The method of claim 35, wherein said amino acid sequence is found in *Streptococcus agalactiae*.

Claim 37. (New) The method of claim 35, wherein said peptide comprises SEQ ID NO: 13.

Claim 38. (New) The method of claim 37, wherein said peptide is encoded by a polynucleotide comprising SEQ ID NO: 12.

Claim 39. (New) The method of claim 35, wherein said peptide further comprising a heterologous peptide.

Claim 40. (New) The method of claim 39, wherein said heterologous peptide is a His tag.

Claim 41. (New) The method of claim 35, wherein said composition further comprises a carrier.

Claim 42. (New) The method of claim 41, wherein said composition further comprises an adjuvant.

Claim 43. (New) The method of claim 42, wherein said adjuvant is alum.

Claim 44. (New) The method of claim 35, wherein said subject is an animal.

Claim 45. (New) The method of claim 44, wherein said animal is a human or a cow.

Claim 46. (New) The method of claim 35, wherein said composition elicits an immune response.

Claim 47. (New) The method of claim 35, wherein said disease or disorder is selected from the group consisting of: a Group B *Streptococcus* infection, septicaemia, pneumonia, osteomyelitis, septic arthritis, abscesses, endophthalmitis, urinary track infection, and chronic mastitis.

Claim 48. (New) The method of claim 47, wherein said disease or disorder is a Group B *Streptococcus* infection.

Claim 49. (New) The method of claim 47, wherein said disease or disorder is a urinary track infection.